Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $195.00. The company’s shares closed last Friday at $164.99 ...

AbbVie stock fell 10% after emraclidine, its drug for schizophrenia, failed during the final stages of its trials. The ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...

Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

The pharma is trying to win court backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead ...